What Tests Are Needed During FIP Medication Treatment

Feline Infectious Peritonitis (FIP) is a devastating disease in cats, caused by mutations in feline coronavirus (FCoV). The introduction of antiviral medications, such as GS-441524 and remdesivir, has transformed FIP from an invariably fatal illness into one with hope for recovery. Monitoring cats during treatment, however, is essential. This article provides a comprehensive guide to the necessary tests during FIP medication therapy, offering a practical approach tailored for veterinarians and cat owners in the United States.

The Landscape of FIP

FIP was once considered nearly untreatable, with fatality rates approaching 100%. The clinical presentation varies, but FIP is typically divided into "wet" (effusive) and "dry" (non-effusive) forms. This distinction impacts both diagnosis and the course of therapeutic monitoring. The standard medications used in treating FIP, especially nucleoside analogs, require close observation to measure efficacy and detect adverse reactions promptly.

Goals of Testing During FIP Treatment

The primary goals of ongoing testing are:

To monitor clinical progress and drug effectiveness.

To identify and manage potential side effects of antiviral medications.

To track organ system involvement and recovery.

To provide timely support if complications emerge.

Baseline Tests Before Starting Medication

Prior to initiating any FIP medication, veterinarians should conduct several baseline tests:

1. Complete Blood Count (CBC)

A CBC evaluates red and white blood cells as well as platelet counts. Abnormalities common in FIP include anemia and neutrophilia; a baseline helps understand subsequent changes.

2. Serum Biochemistry Profile

This profile assesses liver enzymes (ALT, AST), kidney values (creatinine, BUN), albumin, globulin, and total protein. Cats with FIP often have hyperglobulinemia and low albumin.

3. FCoV Antibody/RT-PCR

While not directly monitoring therapy, confirming FCoV infection helps support the diagnosis of FIP.

4. Imaging Studies (Ultrasound/X-rays)

Imaging detects effusions in wet FIP and organ involvement in the dry form. Baseline scans map the disease’s extent.

5. Urinalysis

A urinalysis examines kidney function and screens for secondary infections, critical for tracking medication impact.

Regular Testing During Therapy

After starting medication, repeat tests are essential. Frequency depends on severity, medication protocol, and clinical progress.

1. CBC Monitoring

Frequency: Biweekly for the first month, then monthly.

CBC is repeated to watch for improvement in anemia and white cell counts. Quickly rising neutrophils or new cytopenias may indicate infection or drug reaction.

2. Serum Biochemistry Monitoring

Frequency: Biweekly initially, then monthly.

Liver and kidney values should normalize with successful FIP therapy; any acute changes could signal toxicity or complications needing medical intervention.

Albumin-to-Globulin Ratio: Used as a prognostic marker for disease resolution. Ratios below 0.8 suggest severe FIP, improving ratios indicate recovery.

3. Acute Phase Proteins (APPs)

Frequency: Monthly.

Some clinics use serum amyloid A or alpha-1-acid glycoprotein to follow inflammation. APPs should fall as cats respond.

4. Imaging Follow-Up

Frequency: Monthly or as needed.

Ultrasound or radiographs track the resolution of effusions, granulomas, or enlarged organs. Imaging is especially key in dry FIP cases.

5. FCoV RT-PCR or Antibody Titer

Frequency: Once a month or as clinically indicated.

While viral loads are not always accessible, a decline in PCR or titer results, although variable, may support progress. They are not sole markers of treatment success.

Additional Tests Based on Clinical Needs

1. Coagulation Profile

Cats with abdominal effusion may be at risk for clotting issues (DIC). A coagulation panel helps tailor supportive therapies.

2. Fluid Analysis

If effusions persist, periodic analysis of abdominal or thoracic fluid can assess protein levels, cellular makeup, and viral presence.

3. Renal and Hepatic Panels

Some FIP medications, especially GS-441524, may impact liver and kidney function. Panels can prevent irreversible damage.

4. Blood Pressure Measurement

Hypertension is rare but possible, especially in cats with chronic renal impairment or high-dose therapy.

5. Electrolyte Panel

Vomiting, anorexia, or medication side effects may disrupt sodium, potassium, calcium, or phosphorus, all requiring monitoring.

Drug-Specific Monitoring

GS-441524 and Remdesivir

These medications are commonly used against FIP. Though considered generally safe, monitoring for side effects such as neutropenia, anemia, and mild elevations in liver enzymes is essential.

Mutian, Xraphconn, and Other Nucleoside Analogues

While dosing protocols vary, side effects do overlap. Regular monitoring is needed to address any changes in bloodwork or organ function.

Special Considerations: Neuro and Ocular FIP

Cats with neurological or ocular FIP require tailored testing:

Neurological Exams: Regular monitoring for seizure activity, gait changes, or visual impairment.

CSF Analysis: In severe neurological cases, analysis of cerebrospinal fluid may be indicated to measure protein or inflammatory cells.

These forms often need higher doses of medication and more frequent testing.

Clinical Scenarios Requiring Prompt Testing

Sudden change in appetite or behavior

Development of jaundice or pale gums

New respiratory symptoms

Ascites, pleural fluid, or abdominal distention increase

Worsening neurological signs

Rapid testing in these scenarios can confirm complications or rule out medication toxicity.

How Test Results Guide Therapy Adjustments

The laboratory and imaging findings provide guideposts for therapy duration (usually 12 weeks), dose adjustments, or supportive therapies. Resolution of cytopenias, normal APPs, improved A:G ratios and normalization of imaging studies all indicate therapy success. Persistently abnormal tests may mean protocol extension or dose escalation.

Home Monitoring Between Veterinary Visits

While laboratory work is crucial, owners should monitor:

Activity level

Appetite, drinking, urination

Gum color

Body weight

Ability to jump/climb (for neuro/ocular FIP)

Owners should report changes immediately. Close communication between veterinarian and owner improves outcomes.

Considerations for Relapse and Re-testing

Some cats relapse after initial improvement. In these cases, the same battery of tests should be repeated, with additional focus on viral load and APPs to distinguish between a new infection, drug resistance, or another illness.

Financial and Emotional Aspects

FIP treatment can be expensive, with repeated testing adding substantial cost. Owners should work with veterinarians to prioritize tests critical for safety and efficacy, balancing thorough monitoring with financial sustainability.

Practical Testing Timetable

| Timepoint | Key Tests |

||-|

| Before Therapy | CBC, biochemistry, imaging, urinalysis, FCoV test |

| Biweekly | CBC, biochemistry (liver, kidney, A:G ratio) |

| Monthly | Imaging, APPs, FCoV titer/PCR, fluid analysis |

| As Needed | Coagulation profile, blood pressure, CSF analysis |

Limitations, Evolving Protocols, and Current Research

FIP therapy and monitoring are still evolving. Newer tests, such as viral quantitation by next-generation sequencing, or more sensitive markers of organ injury, may supplement existing protocols in the future. Always consult updated veterinary guidelines.

References

Dr. Niels Pedersen, “Diagnosis of Feline Infectious Peritonitis: The Problem of Over‐Interpretation,” Journal of Feline Medicine and Surgery (2014)

Dr. Niels Pedersen et al., “Efficacy of GS-441524 for treating feline infectious peritonitis,” Journal of Feline Medicine and Surgery (2019)

Addie, D. D. et al., “Feline Infectious Peritonitis: ABCD Guidelines,” Journal of Feline Medicine and Surgery (2022)

R.W. Hartmann, “Feline Infectious Peritonitis—A Review,” Veterinary Sciences (2020)

Murphy, B. G., “What You Need to Know About GS-441524 and FIP,” Clinical Veterinary Advice (2023)

Tasker S., “Diagnosis and clinical management of feline infectious peritonitis,” Veterinary Clinics of North America: Small Animal Practice (2018)

Ikeda, A., “Current strategy and diagnosis for FIP: risk and management,” Journal of Veterinary Science (2021)

“ACVIM Consensus Statement on Feline Infectious Peritonitis,” Journal of Veterinary Internal Medicine (2021)

“Interpreting blood test results in FIP,” Winn Feline Foundation Symposium Proceedings (2019)

Legendre, A. M., “Current concepts in the treatment and monitoring of FIP,” North American Veterinary Conference Proceedings (2020)